Reference health
Targeting the interleukin pathway in the treatment of asthma
00157-9/badge.svg){kind=icon}
80/80 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
5 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 80 checked references that resolve
resolves10.1159/000338998
The Cost of Persistent Asthma in Europe: An International Population-Based Study in Adults
resolves10.1183/09031936.00202013
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
resolves10.1016/j.jaci.2006.11.639
Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program
resolves10.1183/09031936.03.00261903
The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma
resolves10.1016/j.jaci.2014.06.036
Allergens and the airway epithelium response: Gateway to allergic sensitization
resolves10.1164/rccm.200906-0896OC
Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program
resolves10.1513/AnnalsATS.201304-087AW
How Variability in Clinical Phenotypes Should Guide Research into Disease Mechanisms in Asthma
resolves10.1073/pnas.0707413104
Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids
resolves10.1164/rccm.200903-0392OC
T-helper Type 2–driven Inflammation Defines Major Subphenotypes of Asthma
resolves10.1164/rccm.200701-085OC
A Study to Evaluate Safety and Efficacy of Mepolizumab in Patients with Moderate Persistent Asthma
resolves10.1016/S0140-6736(12)60988-X
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
resolves10.1016/j.rmed.2014.10.007
Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR)
resolves10.1136/thoraxjnl-2014-205634
External validation of blood eosinophils, FE
<sub>NO</sub>
and serum periostin as surrogates for sputum eosinophils in asthma
resolves10.1016/j.jaci.2013.07.036
Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma
resolves10.1513/AnnalsATS.201310-354OC
Blood Eosinophil Count Is a Useful Biomarker to Identify Patients with Severe Eosinophilic Asthma
resolves10.1016/j.jaci.2012.06.025
Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients
resolves10.1164/rccm.200312-1651OC
Effects of Treatment with Anti-immunoglobulin E Antibody Omalizumab on Airway Inflammation in Allergic Asthma
resolves10.1164/ajrccm.155.6.9196082
The Effect of an Anti-IgE Monoclonal Antibody on the Early- and Late-Phase Responses to Allergen Inhalation in Asthmatic Subjects
resolves10.1111/j.1398-9995.2008.01881.x
Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti‐IgE treatment
resolves10.1111/j.1398-9995.2004.00772.x
Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
resolves10.1111/cea.12400
Pharmacokinetics, pharmacodynamics and safety of <scp>QGE</scp>031 (ligelizumab), a novel high‐affinity anti‐IgE antibody, in atopic subjects
resolves10.1126/scitranslmed.3008961
Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production
resolves10.1016/S0140-6736(07)61600-6
Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies
resolves10.1016/j.jaci.2012.03.030
IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti–IL-4 receptor α antagonist
resolves10.1164/rccm.200909-1448OC
A Randomized, Controlled, Phase 2 Study of AMG 317, an IL-4Rα Antagonist, in Patients with Asthma
resolves10.1111/cea.12220
The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge
resolves10.1136/thoraxjnl-2014-206719
Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies
resolves10.1183/09031936.00223411
A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma
resolves10.1016/S2213-2600(15)00197-6
Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial
resolves10.1016/j.jaci.2014.01.002
Efficacy and safety of an anti–IL-13 mAb in patients with severe asthma: A randomized trial
resolves10.1016/S0140-6736(00)03496-6
Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response
resolves10.1056/NEJMoa1403291
Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
resolves10.1164/rccm.201103-0396OC
Reslizumab for Poorly Controlled, Eosinophilic Asthma: A Randomized, Placebo-controlled Study
resolves10.1016/S2213-2600(15)00042-9
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials
resolves10.1016/S2213-2600(14)70201-2
Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study
resolves10.1016/j.ajem.2014.09.036
A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma
resolves10.1164/ajrccm.160.6.9808146
Interleukin-4 Receptor in Moderate Atopic Asthma: A Phase I/II Randomized, Placebo-controlled Trial
resolves10.1067/mai.2001.115624
Efficacy of soluble IL-4 receptor for the treatment of adults with asthma
resolves10.1016/j.jaci.2013.03.051
Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids
resolves10.1056/NEJMe1408614
Anti–Interleukin-5 Monoclonal Antibody to Treat Severe Eosinophilic Asthma
resolves10.1016/j.jaci.2010.04.004
MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function
resolves10.4049/jimmunol.0900904
Proteases Induce Production of Thymic Stromal Lymphopoietin by Airway Epithelial Cells through Protease-Activated Receptor-2
resolves10.4049/jimmunol.1201165
MicroRNA-375 Regulation of Thymic Stromal Lymphopoietin by Diesel Exhaust Particles and Ambient Particulate Matter in Human Bronchial Epithelial Cells
resolves10.1146/annurev.immunol.25.022106.141718
TSLP: An Epithelial Cell Cytokine that Regulates T Cell Differentiation by Conditioning Dendritic Cell Maturation
resolves10.1016/j.jaci.2009.12.935
Increased IL-33 expression by epithelial cells in bronchial asthma
resolves10.4049/jimmunol.181.4.2790
Expression and Cellular Provenance of Thymic Stromal Lymphopoietin and Chemokines in Patients with Severe Asthma and Chronic Obstructive Pulmonary Disease
resolves10.1002/cbf.2926
Thymic stromal lymphopoietin promotes asthmatic airway remodelling in human lung fibroblast cells through STAT3 signalling pathway
resolves10.1056/NEJMoa1402895
Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic Responses
resolves10.1038/nrd2266
Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases
resolves10.1111/j.1365-2222.2011.03813.x
A randomized, double‐blind, placebo‐controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma
resolves10.1016/j.jaci.2012.10.013
Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients
resolves10.1016/j.pupt.2015.03.003
Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment
resolves10.1183/13993003.congress-2015.OA290
LATE-BREAKING ABSTRACT: Effect of QAW039, an oral prostaglandin D2 receptor (DP2/CRTh2) antagonist, upon bronchial epithelial integrity in treatment-resistant asthma in a randomized, placebo controlled study
resolves10.4049/jimmunol.0903162
IL-17 Promotes p38 MAPK-Dependent Endothelial Activation Enhancing Neutrophil Recruitment to Sites of Inflammation
resolves10.1016/j.imbio.2014.09.016
Mode of dendritic cell activation: The decisive hand in Th2/Th17 cell differentiation. Implications in asthma severity?
resolves10.1164/rccm.201212-2318OC
Randomized, Double-Blind, Placebo-controlled Study of Brodalumab, a Human Anti–IL-17 Receptor Monoclonal Antibody, in Moderate to Severe Asthma
resolves10.1183/09031936.00048509
SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects
resolves10.1111/j.1365-2222.2012.04014.x
Safety and efficacy of a <scp>CXCR</scp>2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo‐controlled clinical trial
resolves10.1136/thx.2007.086314
The role of a soluble TNF receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial
resolves10.1164/rccm.200809-1512OC
A Randomized, Double-blind, Placebo-controlled Study of Tumor Necrosis Factor-α Blockade in Severe Persistent Asthma
The 5 references without a DOI — listed, not checked
no DOI — not checkedAsthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies
no DOI — not checkedDjukanovic R, Wilson SJ, Kraft M, et al. Effect of treatment with anti-IgE antibody (omalizumab) on airway inflammation in mild atopic asthma. American Thoracic Society 99th international conference; Seattle, WA, USA; May 16–21, 2003. Abstract 703.
no DOI — not checkedOmalizumab for asthma in adults and children
no DOI — not checkedWenzel SEIP, Otulana BA, Bleecker ER, et al. Inhaled pitrakinra, an IL-4/IL-13 antagonist reduced exacerbations in patients with eosinophilic asthma. ERS annual congress 2010; Barcelona; Sept 18–22, 2010. Abstract 3980.
no DOI — not checkedWenzel SE, Wang L, Pirozzi G, et al. Dupilumab improves lung function and reduces severe exacerbations in uncontrolled asthmatics with baseline eosinophil levels above and below 300 cells/μl. 2015 Meeting of the American Thoracic Society; Denver, CO, USA; May 15–20, 2015. Abstract A6362.
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1016/s0140-6736(15)00157-9"><img src="https://citestamp.com/citestamped/10.1016/s0140-6736(15)00157-9/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[00157-9/badge.svg)](https://citestamp.com/citestamped/10.1016/s0140-6736(15)00157-9)